Up­dat­ed: Im­muno­vant will not take rare dis­ease drug to reg­u­la­tors de­spite Phase 3 win

Im­muno­vant will not seek ap­proval for its can­di­date for the au­toim­mune dis­or­der myas­the­nia gravis (MG), de­spite a rea­son­able show­ing in its piv­otal tri­al. In­stead, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER